Cell-free synthesis of connexin 43-integrated exosome-mimetic nanoparticles for siRNA delivery - PubMed (original) (raw)
Cell-free synthesis of connexin 43-integrated exosome-mimetic nanoparticles for siRNA delivery
Mei Lu et al. Acta Biomater. 2019.
Abstract
Exosomes are naturally secreted nanovesicles that have emerged as a promising therapeutic nanodelivery platform, due to their specific composition and biological properties. However, challenges like considerable complexity, low isolation yield, drug payload, and potential safety concerns substantially reduce their pharmaceutical acceptability. Given that the nano-bio-interface is a crucial factor for nanocarrier behavior and function, modification of synthetic nanoparticles with the intrinsic hallmarks of exosomes' membrane to create exosome mimetics could allow for siRNA delivery in a safer and more efficient manner. Herein, connexin 43 (Cx43)-embedded, exosome-mimicking lipid bilayers coated chitosan nanoparticles (Cx43/L/CS NPs) were constructed by using cell-free (CF) synthesis systems with plasmids encoding Cx43 in the presence of lipid-coated CS NPs (L/CS NPs). The integration of de novo synthesized Cx43 into the lipid bilayers of L/CS NPs occurred cotranslationally during one-pot reaction and, more importantly, the integrated Cx43 was functionally active in transport. In addition to considerably lower cytotoxicity (<four-fold) than cationic Lipo 2000, the obtained Cx43/L/CS-siRNA NPs showed feasible cellular uptake and silencing efficacy that was significantly higher than free siRNA and CS-siRNA NPs. By using a gap junction (GJ) inhibitor, 18β-glycyrrhetinic acid, we demonstrated that Cx43 facilitated the delivery of siRNA into Cx43-expressing U87 MG cells. Additionally, the cellular entry of Cx43/L/CS-siRNA NPs may rely on different endocytic mechanisms, depending on the types of recipient cells. However, Cx43/L/CS-siRNA NPs still exhibited far from adequate delivery efficiency compared with transfection reagent Lipo 2000. Taken together, our study provides a brand new strategy to construct Cx43-functionalized, exosome-mimetic nanoparticles, which may further encourage the establishment of more biomimetic nanocarriers with higher biocompatibility and delivery efficiency. SIGNIFICANCE OF STATEMENT: The major issue to move RNA interference (RNAi) therapy from bench to bedside is the lack of safe and efficient delivery vehicles. Given the certain advantages and limitations of exosomes and synthetic nanocarriers, a promising strategy is to facilitate positive feedbacks between the two fields, in which the superiority of exosomes regarding special membrane composition beneficial for cytoplasmic delivery and the better pharmaceutical acceptance of synthetic nanocarriers could be combined. In this study, we reported to construct Cx43-integrated, exosome-mimetic lipid bilayers coated nanoparticles by using CF synthesis technique. The obtained Cx43/L/CS-siRNA NPs were characterized by desirable cytotoxicity profile and feasible delivery efficiency. This study provides a new avenue and insights for the synthesis of more biocompatible and effective bio-mimetic siRNA delivery platforms.
Keywords: Cell-free protein synthesis; Chitosan nanoparticles; Connexin 43; Exosomes; Lipid bilayers; siRNA delivery.
Copyright © 2019 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
Similar articles
- Comparison of exosome-mimicking liposomes with conventional liposomes for intracellular delivery of siRNA.
Lu M, Zhao X, Xing H, Xun Z, Zhu S, Lang L, Yang T, Cai C, Wang D, Ding P. Lu M, et al. Int J Pharm. 2018 Oct 25;550(1-2):100-113. doi: 10.1016/j.ijpharm.2018.08.040. Epub 2018 Aug 20. Int J Pharm. 2018. PMID: 30138707 - One-Step Production Using a Microfluidic Device of Highly Biocompatible Size-Controlled Noncationic Exosome-like Nanoparticles for RNA Delivery.
Kimura N, Maeki M, Ishida A, Tani H, Tokeshi M. Kimura N, et al. ACS Appl Bio Mater. 2021 Feb 15;4(2):1783-1793. doi: 10.1021/acsabm.0c01519. Epub 2021 Jan 12. ACS Appl Bio Mater. 2021. PMID: 35014524 - Biomimetic cell membrane-coated nanocarriers for targeted siRNA delivery in cancer therapy.
Huang X, Guo H, Wang L, Zhang Z, Zhang W. Huang X, et al. Drug Discov Today. 2023 Apr;28(4):103514. doi: 10.1016/j.drudis.2023.103514. Epub 2023 Feb 2. Drug Discov Today. 2023. PMID: 36736580 Review. - Arrowtail RNA for Ligand Display on Ginger Exosome-like Nanovesicles to Systemic Deliver siRNA for Cancer Suppression.
Li Z, Wang H, Yin H, Bennett C, Zhang HG, Guo P. Li Z, et al. Sci Rep. 2018 Oct 2;8(1):14644. doi: 10.1038/s41598-018-32953-7. Sci Rep. 2018. PMID: 30279553 Free PMC article. - Bioinspired exosome-like therapeutics and delivery nanoplatforms.
Lu M, Huang Y. Lu M, et al. Biomaterials. 2020 Mar 2;242:119925. doi: 10.1016/j.biomaterials.2020.119925. Online ahead of print. Biomaterials. 2020. PMID: 32151860 Review.
Cited by
- Cutting-Edge HEK293T Protein-Integrated Lipid Nanostructures: Boosting Biocompatibility and Efficacy.
Park JH, Bai CZ, Kwak JH, Choi HJ, Lee D, Hong HE, Kim OH, Kim SJ. Park JH, et al. Int J Mol Sci. 2024 Mar 14;25(6):3294. doi: 10.3390/ijms25063294. Int J Mol Sci. 2024. PMID: 38542268 Free PMC article. - Connexin-Containing Vesicles for Drug Delivery.
Hanafy MS, Cui Z. Hanafy MS, et al. AAPS J. 2024 Jan 24;26(1):20. doi: 10.1208/s12248-024-00889-8. AAPS J. 2024. PMID: 38267725 Review. - Role of lysosome in healing neurological disorders by nano-bioengineering.
Raj A, Bandyopadhyay U. Raj A, et al. Front Neurosci. 2024 Jan 8;17:1331211. doi: 10.3389/fnins.2023.1331211. eCollection 2023. Front Neurosci. 2024. PMID: 38260032 Free PMC article. Review. - The complexity of nicotinamide adenine dinucleotide (NAD), hypoxic, and aryl hydrocarbon receptor cell signaling in chronic kidney disease.
Curran CS, Kopp JB. Curran CS, et al. J Transl Med. 2023 Oct 9;21(1):706. doi: 10.1186/s12967-023-04584-8. J Transl Med. 2023. PMID: 37814337 Free PMC article. Review. - Antitumor synergism between PAK4 silencing and immunogenic phototherapy of engineered extracellular vesicles.
Lu M, Xing H, Shao W, Wu P, Fan Y, He H, Barth S, Zheng A, Liang XJ, Huang Y. Lu M, et al. Acta Pharm Sin B. 2023 Sep;13(9):3945-3955. doi: 10.1016/j.apsb.2023.03.020. Epub 2023 Mar 29. Acta Pharm Sin B. 2023. PMID: 37719367 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous